In a sign of weak demand, NxStage Medical, a marketer of a homecare hemodialysis system for end-stage renal disease, lowered its proposed range to $11-$12 from $13-$15. The offering size remains the same at 5.5 million shares. Merrill Lynch will be the lead manager on the deal, which is slated to price tonight and begin trading on the NASDAQ Thursday under the ticker "NXTM."
